<DOC>
	<DOCNO>NCT00968669</DOCNO>
	<brief_summary>To study effectiveness safety multiple-doses MEDI-528 asthma control adult participant uncontrolled , moderate-to-severe , persistent asthma .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety MEDI-528 Adults</brief_title>
	<detailed_description>The primary objective study evaluate effect multiple-dose subcutaneous ( SC ) administration MEDI-528 asthma control adult uncontrolled , moderate-to-severe , persistent asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet following criterion : 1 . Male female 2 . Age 18 65 year time screen 3 . Written inform consent locally require authorization obtain subject prior performing protocolrelated procedure , include screen evaluation 4 . Female subject childbearing potential sexually active nonsterilized male partner must use adequate contraception screen end study . An acceptable method contraception define one high 1 % failure rate . Sustained abstinence acceptable practice ; however , periodic abstinence , rhythm method , withdrawal method acceptable method contraception 1 . Nonsterilized male sexually active female childbearing potential must use adequate contraception screen end study 2 . Females female partner childbearing potential must surgically sterilize ( eg , hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( define least 1 year since last regular menses ) 3 . Sterilized male must least 1year post vasectomy obtain documentation absence sperm ejaculate 5 . Weight ≥ 45 kg ≤ 120 kg body mass index ( BMI ) 18 35 kg/m2 6 . Physiciandiagnosed asthma medical chart 7 . Currently take inhale corticosteroid ( ICS ) candidate receive ICS per Expert Panel Report ( EPR ) 3 8 . Prebronchodilator force expiratory volume 1 second ( FEV1 ) value ≥ 40 % Day 28 Day 1 9 . A postbronchodilator increase FEV1 and/or FVC ≥ 12 % ≥ 200 mL Day 28 OR meet one follow criterion : 1 . Proof postbronchodilator reversibility airflow obstruction ≥ 12 % document within 36 month prior randomization proof positive response methacholine challenge document within 36 month prior randomization ; OR 2 . Proof partial reversibility ≥ 8 % &lt; 12 % improvement postbronchodilator FEV1 Day 28 achievement ≥ 12 % reversibility second time Day 27 Day 15 ; OR 3 . If ) b ) meet inclusion/exclusion criterion meet , subject FEV1 ≥ 1.5 L ≥ 60 % Day 14 eligible undergo methacholine challenge . If subject achieves positive response methacholine challenge , criterion meet 10 . Uncontrolled asthma consistent EPR3 . In 28 day screen , subject history one following : Daytime asthma symptom ≥ 2 days/week Nighttime awaken ≥ 1 night/week Albuterol/salbutamol use ≥ 2 days/week 11 . An Asthma Control Questionnaire ( ACQ ) score ≥ 1.5 Day 28 Day 1 . 12 . At least one asthma exacerbation 12 month screen required intake systemic corticosteroid unscheduled medical encounter agree physician base asthma action plan define oral steroid take subject 13 . Ability willingness complete followup period Day 323 require protocol . Exclusion Criteria Any follow would exclude subject participation study : 1 . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result 2 . Concurrent enrollment another clinical study 3 . Employees clinical study site individual involve conduct study , immediate family member individual 4 . Known history allergy reaction component investigational product formulation 5 . History anaphylaxis biologic therapy 6 . Lung disease asthma ( eg , chronic obstructive pulmonary disease [ COPD ] , cystic fibrosis ) 7 . Severe depression measure depression score &gt; 15 Hospital Anxiety Depression Scale ( HADS ) either Day28 Day 1 . 8 . History suicidal behavior previous 3 year measure Columbia Suicide Severity Rating Scale ( CSSRS ) Day 28 . 9 . Acute illness asthma screen randomization visit 10 . History active infection within 28 day screen period , evidence clinically significant active infection , include ongoing chronic infection 11 . History ingestion untreated water location know infected parasite , result acute chronic diarrhea ; history recent travel area parasite infestation endemic within 6 month screen ; diagnosis parasitic infection within 6 month screen 12 . Use immunosuppressive medication ( except oral prednisone dose 20 mg every day equivalent [ eg , 10 mg day 5 mg twice day ] inhale topical corticosteroid ) within 28 day randomization 13 . Receipt immunoglobulin blood product within 28 day randomization 14 . Plans donate blood entire study period 15 . Donated blood blood transfusion within 28 day screen 16 . Receipt nonbiological study drug interventional therapy ( include surgical procedure ) within 28 day first dose investigational product study 17 . Receipt biologicals include MEDI528 within 5 halflives first dose investigational product study 18 . History known immunodeficiency disorder 19 . A positive hepatitis B surface antigen , hepatitis C virus antibody , determine medical history and/or subject 's verbal report 20 . A positive human immunodeficiency virus test take antiretroviral medication , determine medical history and/or subject 's verbal report 21 . A live attenuated vaccination receive within 28 day screen 22 . History clinically significant abnormality electrocardiogram ( ECG ) opinion investigator 23 . Breastfeeding lactate 24 . History treatment alcohol drug abuse within past year 25 . History suggestive COPD tobacco smoke ≥ 10 packyears 26 . Evidence uncontrolled systemic disease upon physical examination 27 . History cancer , apart basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy ≥ 1 year Day 1 malignancy treat apparent success curative therapy ≥ 5 year screen 28 . Any noninfectious disease involve multiple organ ( eg , cystic fibrosis , systemic lupus erythematosus , hemophilia , multiple sclerosis , etc . ) , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result 29 . Individuals legally institutionalize</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>